FDA Letter API

VitaCig Canada

Letter data

Company
VitaCig Canada
Recipient
Ki-Il Kim | VitaCig Canada | United States | vitacigcad@gmail.com | support@vitacig-canada.com | nibocnc@gmail.com
Issue date
2020-10-22
Posted date
Not available
FDA office
Center for Tobacco Products
Subject
Not available
Product
Not available
CMS ID
597072
Reference number
RW1901215
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER VitaCig Canada MARCS-CMS 597072 — October 22, 2020 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: RW1901215 Recipient: Recipient Name Ki-Il Kim VitaCig Canada United States vitacigcad@gmail.com support@vitacig-canada.com nibocnc@gmail.com Issuing Office: Center for Tobacco Products United States Dear Ki-Il Kim: The United States Food and Drug Administration’s (FDA) Center for Tobacco Products has completed an evaluation of your corrective actions included in your responses, dated November 27, 2019 and December 9, 2019, in response to our Warning Letter dated November 26, 2019. Based on our evaluation, it appears that you have taken steps to address the violations contained in the Warning Letter regarding your website https://www.vitacig-canada.com. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Sincerely, /S/ David Rice Branch Chief Division of Promotion, Advertising, and Labeling Office of Compliance and Enforcement Center for Tobacco Products Content current as of: 10/26/2020